Pipeline

Program/
Therapeutic Area
Target(s)
Format
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Commercialization Rights
INBRX-109
Oncology
DR5
Multivalent Agonist
/ ROW; Just China / China
INBRX-105
Oncology
PD-L1, 4-1BB
Conditional Immune Activator
/ ROW; ELPI Science / China
INBRX-101
Orphan/Respitory
NE
Fusion Protein
INBRX-103
Oncology
CD47
Conventional mAb
INBRX-106
Oncology
OX40
Multivalent Agonist
/ ROW; ELPI Science / China
INBRX-110
Oncology
GITR
Multivalent
INBRX-107
Oncology
Checkpoint inhibitors
Conditional Immune Activator
INBRX-113
Oncology
B7H3
Constrained T-cell Engager
INBRX-114
Oncology
DLL3
Constrained T-cell Engager
INBRX-111
Pseudomonas aeruginosa
PCRV,OPRI
Multi-functional Anti-infective
INBRX-117
Oncology
Asparagine
Asparaginase-sdAb fusion

Program/
Therapeutic Area
Target(s)
Format
Stage of Discovery
INBRX-109
Oncology
DR5
Multivalent Agonist
Phase 1
INBRX-105
Oncology
PD-L1, 4-1BB
Conditional Immune Activator
Phase 1
INBRX-101
Orphan/ Respitory
NE
Fusion Protein
Phase 1
INBRX-103
Oncology
CD47
Conventional mAb
Phase 1
INBRX-106
Oncology
OX40
Multivalent Agonist
Discovery
INBRX-110
Oncology
GITR
Multivalent
Discovery
INBRX-107
Oncology
Checkpoint inhibitors
Conditional Immune Activator
Discovery
INBRX-113
Oncology
B7H3
Constrained T-cell Engager
Discovery
INBRX-114
Oncology
DLL3
Constrained T-cell Engager
Discovery
INBRX-111
Pseudomonas aeruginosa
PCRV,OPRI
Multi-functional Anti-infective
Discovery
INBRX-117
Oncology
Asparagine
Asparaginase-sdAb fusion
Discovery